D. Tougeron, T. Lecomte, and J. Pages, Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Annals of Oncology, vol.24, issue.5, pp.1267-1273, 2013.
DOI : 10.1093/annonc/mds620

A. Jemal, F. Bray, and M. Center, Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011.
DOI : 10.3322/caac.20107

W. De-roock, H. Piessevaux, D. Schutter, and J. , KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-515, 2008.
DOI : 10.1093/annonc/mdm496

D. Fiore, F. Blanchard, F. Charbonnier, and F. , Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1169, 2007.
DOI : 10.1093/jnci/92.3.205

S. Khambata-ford, C. Garrett, and N. Meropol, Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

A. Lievre, J. Bachet, and V. Boige, Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008.
DOI : 10.1200/JCO.2007.12.5906

URL : https://hal.archives-ouvertes.fr/hal-00363737

J. Douillard, K. Oliner, and S. Siena, Mutations in Colorectal Cancer, New England Journal of Medicine, vol.369, issue.11, pp.1023-1034, 2013.
DOI : 10.1056/NEJMoa1305275

M. Sorich, M. Wiese, and R. A. , Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials, Ann Oncol, 2014.

H. Linardou, I. Dahabreh, and D. Kanaloupiti, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations, Lancet Oncol. Crit Rev Oncol Hematol, vol.9, issue.85, pp.962-972, 2008.

P. Laurent-puig, A. Cayre, and G. Manceau, Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5930, 2009.
DOI : 10.1200/JCO.2008.21.6796

URL : https://hal.archives-ouvertes.fr/hal-00618089

G. Perkins, A. Lievre, and C. Ramacci, Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6
DOI : 10.1002/ijc.25152

F. Chergui, A. Chretien, and S. Bouali, Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1336, 2009.
DOI : 10.1373/clinchem.2008.116632

F. Harrell, J. Lee, K. Mark, and D. , MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-387, 1996.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

W. Sauerbrei, M. Schumacher, M. Sorich, M. Wiese, and R. A. , A bootstrap resampling procedure for model building: Application to the cox regression model, Statistics in Medicine, vol.42, issue.16, pp.2093-2109, 1992.
DOI : 10.1002/sim.4780111607

C. Bokemeyer, E. Van-cutsem, and P. Rougier, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials, European Journal of Cancer, vol.48, issue.10, pp.1466-1475, 2012.
DOI : 10.1016/j.ejca.2012.02.057

S. Iwamoto, S. Hazama, and T. Kato, Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study, Anticancer Res, vol.34, pp.1967-1973, 2014.

R. Newbold, Mutant ras proteins and cell transformation, Nature, vol.310, issue.5979, pp.628-629, 1984.
DOI : 10.1038/310628a0

E. Razis, G. Pentheroudakis, and G. Rigakos, EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab, Journal of Cancer Research and Clinical Oncology, vol.351, issue.4, pp.737-748, 2014.
DOI : 10.1158/0008-5472

M. Scartozzi, R. Giampieri, and E. Maccaroni, Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab, Journal of Translational Medicine, vol.10, issue.1, pp.1479-5876, 2012.
DOI : 10.1245/s10434-009-0864-z

O. Saglam, C. Garrett, and D. Boulware, Activation of the Serine/Threonine Protein Kinase AKT During the Progression of Colorectal Neoplasia, Clinical Colorectal Cancer, vol.6, issue.9, pp.652-656, 2007.
DOI : 10.3816/CCC.2007.n.034

W. De-roock, D. Vriendt, V. Normanno, and N. , KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, The Lancet Oncology, vol.12, issue.6, pp.594-603, 2011.
DOI : 10.1016/S1470-2045(10)70209-6

W. Jeong, P. Cha, and K. Choi, Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer, World Journal of Gastroenterology, vol.20, issue.29, pp.9862-9871, 2014.
DOI : 10.3748/wjg.v20.i29.9862

E. Agarwal, A. Chaudhuri, and P. Leiphrakpam, Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer, BMC Cancer, vol.20, issue.11, pp.1471-2407, 2014.
DOI : 10.1093/emboj/20.11.2723

. Inca, La Situation du Cancer en France en 2012, 2012.

D. Hanahan and R. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

R. Newbold, Mutant ras proteins and cell transformation, Nature, vol.310, issue.5979, pp.628-637, 1984.
DOI : 10.1038/310628a0

E. Chang, M. Furth, E. Scolnick, and D. Lowy, Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus, Nature, vol.31, issue.5866
DOI : 10.1038/297479a0

A. Lievre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3
DOI : 10.1200/JCO.2007.12.5906

URL : https://hal.archives-ouvertes.fr/hal-00363737

S. Stintzing, A. Jung, L. Rossius, D. Modest, L. Fischer-von-weikersthal et al., Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer patients. Presented at: European Cancer Congress 2013 The Netherlands, 2013.

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-62, 2010.
DOI : 10.1016/S1470-2045(10)70130-3

H. Linardou, I. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a 19 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, vol.355, issue.9209, pp.1041-1048, 2000.

C. Tournigand, T. Andre, E. Achille, G. Lledo, M. Flesh et al., FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2
DOI : 10.1200/JCO.2004.05.113

M. Seymour, T. Maughan, J. Ledermann, C. Topham, R. James et al., Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, The Lancet, vol.370, issue.9582, pp.143-52, 2007.
DOI : 10.1016/S0140-6736(07)61087-3

G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso et al., Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell???Italia Meridionale, Journal of Clinical Oncology, vol.23, issue.22, pp.4866-75, 2005.
DOI : 10.1200/JCO.2005.07.113

A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini et al., Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest, Journal of Clinical Oncology, vol.25, issue.13, pp.1670-1676, 2007.
DOI : 10.1200/JCO.2006.09.0928

J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos, N. Ziras et al., FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG), British Journal of Cancer, vol.16, issue.6, pp.798-805, 2006.
DOI : 10.1200/JCO.2004.05.113

M. Ychou, F. Viret, A. Kramar, F. Desseigne, E. Mitry et al., Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases, Cancer Chemotherapy and Pharmacology, vol.23, issue.6, pp.195-201, 2008.
DOI : 10.1007/s00280-007-0588-3

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-705, 2010.
DOI : 10.1200/JCO.2009.27.4860

C. Therkildsen, T. Bergmann, T. Henrichsen-schnack, S. Ladelund, and M. Nilbert, and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis, Acta Oncologica, vol.31, issue.7, pp.852-64, 2014.
DOI : 10.1002/ijc.28153

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Annals of Oncology, vol.25, issue.7, pp.1346-55, 2014.
DOI : 10.1093/annonc/mdu141

. Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer, J Clin Oncol, vol.32, issue.21, pp.2240-2247, 2014.

D. Jonker, O. Callaghan, C. Karapetis, C. Zalcberg, J. Tu et al., Cetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357, issue.20, pp.2040-2048, 2007.
DOI : 10.1056/NEJMoa071834

E. Van-cutsem, C. Kohne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

E. Van-cutsem, C. Kohne, I. Lang, G. Folprecht, M. Nowacki et al., Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.2011-2020, 2011.
DOI : 10.1200/JCO.2010.33.5091

. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, vol.27, issue.5, pp.663-71, 2009.

C. Bokemeyer, I. Bondarenko, J. Hartmann, F. De-braud, G. Schuch et al., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1581, 2011.
DOI : 10.1093/annonc/mdq632

C. Bokemeyer, E. Van-cutsem, P. Rougier, F. Ciardiello, S. Heeger et al., Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials, European Journal of Cancer, vol.48, issue.10, pp.1466-75, 2012.
DOI : 10.1016/j.ejca.2012.02.057

J. Bennouna, J. Sastre, D. Arnold, P. Osterlund, R. Greil et al., Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.1
DOI : 10.1016/S1470-2045(12)70477-1

S. Kubicka, R. Greil, T. Andre, J. Bennouna, J. Sastre et al., Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy, p.18147

F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi, V. Lonati et al., FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials, Clinical Colorectal Cancer, vol.12, issue.3, pp.145-51, 2013.
DOI : 10.1016/j.clcc.2013.04.006

M. Chaix, J. Vincent, V. Lorgis, and F. Ghiringhelli, FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer, Oncology, vol.87, issue.3, pp.148-58, 2014.
DOI : 10.1159/000361031

E. Van-cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausova et al., Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28
DOI : 10.1200/JCO.2012.42.8201

A. Grothey, E. Van-cutsem, A. Sobrero, S. Siena, A. Falcone et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, The Lancet, vol.381, issue.9863, pp.303-315, 2013.
DOI : 10.1016/S0140-6736(12)61900-X

A. Venook, . Calgb, and . Swog, CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)., Journal of Clinical Oncology, vol.32, issue.18_suppl
DOI : 10.1200/jco.2014.32.18_suppl.lba3

P. Jensen and T. Hunter, Oncogenic kinase signalling, 2014 ASCO Annual Meeting, pp.355-65, 2001.

N. Sergina and M. Moasser, The HER family and cancer: emerging molecular mechanisms and therapeutic targets, Trends in Molecular Medicine, vol.13, issue.12, pp.527-561, 2007.
DOI : 10.1016/j.molmed.2007.10.002

P. Hubert, Growth factors of the EGF family and their receptors], Bull Cancer, vol.94, issue.7, 2007.

A. Singh and R. Harris, Autocrine, paracrine and juxtacrine signaling by EGFR ligands, Cellular Signalling, vol.17, issue.10, pp.1183-93, 2005.
DOI : 10.1016/j.cellsig.2005.03.026

A. Gschwind, O. Fischer, and A. Ullrich, Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-70, 2004.
DOI : 10.1038/nrc1360

F. Morgillo, M. Bareschino, R. Bianco, G. Tortora, and F. Ciardiello, Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy, Differentiation, vol.75, issue.9, pp.788-99, 2007.
DOI : 10.1111/j.1432-0436.2007.00200.x

H. Linardou, I. Dahabreh, D. Bafaloukos, P. Kosmidis, and S. Murray, Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC, Nature Reviews Clinical Oncology, vol.58, issue.6, pp.352-66, 2009.
DOI : 10.1038/nrclinonc.2009.62

J. Flynn, C. Wong, and J. Wu, Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer, Journal of Oncology, vol.14, issue.3, p.526963, 2009.
DOI : 10.1038/sj.onc.1208774

J. Mendelsohn and J. Baselga, Epidermal Growth Factor Receptor Targeting in Cancer, Seminars in Oncology, vol.33, issue.4, pp.369-85, 2006.
DOI : 10.1053/j.seminoncol.2006.04.003

T. Miyanaga, J. Hirato, and Y. Nakazato, Amplification of the epidermal growth factor receptor gene in glioblastoma: An analysis of the relationship between genotype and phenotype by CISH method, Neuropathology, vol.65, issue.2
DOI : 10.1007/BF00196514

T. Libermann, H. Nusbaum, N. Razon, R. Kris, I. Lax et al., Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin, Nature, vol.4, issue.5998, pp.144-151, 1985.
DOI : 10.1038/313144a0

D. Veale, T. Ashcroft, C. Marsh, G. Gibson, and A. Harris, Epidermal growth factor receptors in non-small cell lung cancer, British Journal of Cancer, vol.55, issue.5, pp.513-519, 1987.
DOI : 10.1038/bjc.1987.104

M. Azuma, K. Danenberg, S. Iqbal, A. El-khoueiry, W. Zhang et al., Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Variant III Gene Expression in Metastatic Colorectal Cancer, Clinical Colorectal Cancer, vol.6, issue.3, pp.214-222, 2006.
DOI : 10.3816/CCC.2006.n.038

K. Spindler, D. Olsen, J. Nielsen, I. Brandslund, H. Poulsen et al., Lack of the type III epidermal growth factor receptor mutation in colorectal cancer, Anticancer Res, vol.26, issue.6C, pp.4889-93, 2006.

M. Wendt, N. Balanis, C. Carlin, W. Schiemann, A. Larsen et al., STAT3 and epithelial-mesenchymal transitions in carcinomas):e28975. 63 Targeting EGFR and VEGF(R) pathway crosstalk in tumor survival and angiogenesis, Jakstat. Pharmacol Ther, vol.3131, issue.11, pp.80-90, 2011.

C. Boccaccio, P. Luraghi, and P. Comoglio, MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells, Cancer Research, vol.74, issue.14, pp.3647-51, 2014.
DOI : 10.1158/0008-5472.CAN-14-1088

Z. Weihua, R. Tsan, W. Huang, Q. Wu, C. Chiu et al., Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity, Cancer Cell, vol.13, issue.5, pp.385-93, 2008.
DOI : 10.1016/j.ccr.2008.03.015

L. Defize, J. Boonstra, J. Meisenhelder, W. Kruijer, L. Tertoolen et al., Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors, The Journal of Cell Biology, vol.109, issue.5, pp.2495-507, 1989.
DOI : 10.1083/jcb.109.5.2495

F. Ozcan, P. Klein, M. Lemmon, I. Lax, and J. Schlessinger, On the nature of low- and high-affinity EGF receptors on living cells, Proceedings of the National Academy of Sciences, vol.103, issue.15, pp.5735-5775, 2006.
DOI : 10.1073/pnas.0601469103

T. Ringerike, E. Stang, L. Johannessen, D. Sandnes, F. Levy et al., High-affinity Binding of Epidermal Growth Factor (EGF) to EGF Receptor Is Disrupted by Overexpression of Mutant Dynamin (K44A), Journal of Biological Chemistry, vol.273, issue.27, pp.16639-16681, 1998.
DOI : 10.1074/jbc.273.27.16639

J. Krall, E. Beyer, G. Macbeath, S. Minoghchi, and T. Yanagida, High-and low-affinity epidermal growth factor receptorligand interactions activate distinct signaling pathways Single-molecule imaging of EGFR signalling on the surface of living cells, PLoS One. Nat Cell Biol, vol.62, issue.13, pp.168-72, 2000.

Y. Wang, H. Yamaguchi, J. Hsu, and M. Hung, Nuclear trafficking of the epidermal growth factor receptor family membrane proteins, Oncogene, vol.18, issue.28, pp.3997-4006, 2010.
DOI : 10.1042/BST0361373

W. Han and H. Lo, Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations, Cancer Letters, vol.318, issue.2, pp.124-158, 2012.
DOI : 10.1016/j.canlet.2012.01.011

Y. Wang, H. Yamaguchi, L. Huo, Y. Du, H. Lee et al., The Translocon Sec61?? Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus, Journal of Biological Chemistry, vol.285, issue.49, pp.38720-38729, 2010.
DOI : 10.1074/jbc.M110.158659

C. Hirota, F. Moreau, V. Iablokov, M. Dicay, B. Renaux et al., Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX

S. Lin, K. Makino, W. Xia, A. Matin, Y. Wen et al., Nuclear localization of EGF receptor and its potential new role as a transcription factor, Nature Cell Biology, vol.3, issue.9, pp.802-810, 2001.
DOI : 10.1038/ncb0901-802

T. Brand, M. Iida, N. Luthar, M. Starr, E. Huppert et al., Nuclear EGFR as a molecular target in cancer, Radiotherapy and Oncology, vol.108, issue.3, pp.370-377, 2013.
DOI : 10.1016/j.radonc.2013.06.010

W. Huang, Y. Chen, L. Li, Y. Wei, S. Hsu et al., Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells, Journal of Biological Chemistry, vol.286, issue.23, pp.20558-68, 2011.
DOI : 10.1074/jbc.M111.240796

K. Dittmann, C. Mayer, and H. Rodemann, Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity, Radiotherapy and Oncology, vol.76, issue.2, pp.157-61, 2005.
DOI : 10.1016/j.radonc.2005.06.022

G. Liccardi, J. Hartley, and D. Hochhauser, EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment, Cancer Research, vol.71, issue.3, pp.1103-1117, 2011.
DOI : 10.1158/0008-5472.CAN-10-2384

C. Li, M. Iida, E. Dunn, A. Ghia, and D. Wheeler, Nuclear EGFR contributes to acquired resistance to cetuximab, Oncogene, vol.8, issue.43, pp.3801-3814, 2009.
DOI : 10.1038/35052073

S. Hsu, S. Miller, Y. Wang, M. Hung, F. Shepherd et al., Nuclear EGFR is required for cisplatin resistance and DNA repair Erlotinib in previously treated non-small-cell lung cancer, Am J Transl Res. N Engl J Med, vol.1353, issue.822, pp.249-58123, 2005.

T. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009.
DOI : 10.1056/NEJMoa0810699

P. Fumoleau, M. Campone, B. Coudert, F. Mayer, L. Favier et al., Targeting ErbB receptors in breast cancer]. Bull Cancer, pp.147-70, 2007.

C. Boccaccio, G. Gaudino, M. Cilli, A. Mondino, and P. Comoglio, Oncogene, Growth Factors, vol.26, issue.3, pp.233-275, 1991.
DOI : 10.1083/jcb.102.6.2211

S. Swain, S. Kim, J. Cortes, J. Ro, V. Semiglazov et al., Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, The Lancet Oncology, vol.14, issue.6, pp.461-71, 2013.
DOI : 10.1016/S1470-2045(13)70130-X

V. Martin, F. Cappuzzo, L. Mazzucchelli, and M. Frattini, in solid tumors: more than 10 years under the microscope; where are we now?, Future Oncology, vol.10, issue.8, pp.1469-86, 2014.
DOI : 10.2217/fon.14.19

L. Landi and F. Cappuzzo, HER2 and lung cancer, Expert Review of Anticancer Therapy, vol.13, issue.10, pp.1219-1247, 2013.
DOI : 10.1586/14737140.2013.846830

Y. Lu, G. Jingyan, S. Baorong, J. Peng, Y. Xu et al., Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer, Cancer Biomarkers, vol.11, issue.5, pp.219-245, 2012.
DOI : 10.3233/CBM-2012-00282

A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti et al., A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer, Cancer Discovery, vol.1, issue.6, pp.508-531, 2011.
DOI : 10.1158/2159-8290.CD-11-0109

S. Sorscher, Marked response to single agent trastuzumab in a patient with metastatic

D. Amin, M. Campbell, and M. Moasser, The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics, Seminars in Cell & Developmental Biology, vol.21, issue.9, pp.944-50, 2010.
DOI : 10.1016/j.semcdb.2010.08.007

A. Koutras, G. Fountzilas, K. Kalogeras, I. Starakis, G. Iconomou et al., The upgraded role of HER3 and HER4 receptors in breast cancer, Critical Reviews in Oncology/Hematology, vol.74, issue.2, pp.73-81, 2010.
DOI : 10.1016/j.critrevonc.2009.04.011

C. Sartor, H. Zhou, E. Kozlowska, K. Guttridge, E. Kawata et al., Her4 mediates liganddependent antiproliferative and differentiation responses in human breast cancer cells The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells, Mol Cell Biol. Cancer Res, vol.2166, issue.1312, pp.4265-756412, 2001.

C. Lau, K. Killian, Y. Samuels, and U. Rudloff, ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment, Methods Mol Biol, vol.1102, pp.461-80, 2014.
DOI : 10.1007/978-1-62703-727-3_24

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125540

I. Ljuslinder, B. Malmer, M. Isaksson-mettavainio, A. Oberg, R. Henriksson et al., ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases

Y. Soung, J. Lee, S. Kim, Y. Wang, K. Jo et al., kinase domain in human cancers, International Journal of Cancer, vol.62, issue.6, pp.1426-1435, 2006.
DOI : 10.1002/ijc.21507

M. Rokavec, C. Justenhoven, W. Schroth, M. Istrate, S. Haas et al., A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk, Clinical Cancer Research, vol.13, issue.24
DOI : 10.1158/1078-0432.CCR-07-0457

K. Wennerberg, K. Rossman, and C. Der, The Ras superfamily at a glance, Journal of Cell Science, vol.118, issue.5, pp.843-849, 2005.
DOI : 10.1242/jcs.01660

C. Pratilas and D. Solit, Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response, Clinical Cancer Research, vol.16, issue.13, pp.3329-3363, 2010.
DOI : 10.1158/1078-0432.CCR-09-3064

E. Pettersen, T. Goddard, C. Huang, G. Couch, D. Greenblatt et al., UCSF Chimera?A visualization system for exploratory research and analysis, Journal of Computational Chemistry, vol.373, issue.13, pp.1605-1617, 2004.
DOI : 10.1002/jcc.20084

J. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8
DOI : 10.1038/nrc2664

B. Jiang and L. Liu, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1784, issue.1, pp.19-65, 2009.
DOI : 10.1016/j.bbapap.2007.09.008

A. Bellacosa, C. Kumar, D. Cristofano, A. Testa, and J. , Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv Cancer Res, vol.94, pp.29-86, 2005.
DOI : 10.1016/S0065-230X(05)94002-5

M. Macaluso, G. Russo, C. Cinti, V. Bazan, N. Gebbia et al., Ras family genes: An interesting link between cell cycle and cancer, Journal of Cellular Physiology, vol.139, issue.2, pp.125-155, 2002.
DOI : 10.1002/jcp.10109

D. Planchard, Y. Loriot, and B. Besse, Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value], Bull Cancer, vol.96, pp.57-68, 2009.

F. Bibeau, H. Frugier, A. Denouel, J. Sabourin, and F. Boissiere-michot, Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view], Bull Cancer, vol.96, pp.15-22, 2009.

M. Beeram, A. Patnaik, and E. Rowinsky, Raf: A Strategic Target for Therapeutic Development Against Cancer, Journal of Clinical Oncology, vol.23, issue.27, pp.6771-90, 2005.
DOI : 10.1200/JCO.2005.08.036

C. Wellbrock, M. Karasarides, and R. Marais, The RAF proteins take centre stage, Nature Reviews Molecular Cell Biology, vol.9, issue.11, pp.875-85, 2004.
DOI : 10.1096/fj.02-1096com

E. Halilovic and D. Solit, Therapeutic strategies for inhibiting oncogenic BRAF signaling, Current Opinion in Pharmacology, vol.8, issue.4, pp.419-445, 2008.
DOI : 10.1016/j.coph.2008.06.014

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

B. Karakas, K. Bachman, and B. Park, Mutation of the PIK3CA oncogene in human cancers, British Journal of Cancer, vol.14, issue.4, pp.455-464, 2006.
DOI : 10.1016/j.ceb.2005.02.011

Y. Samuels and V. Velculescu, Oncogenic Mutations of PIK3CA in Human Cancers, Cell Cycle, vol.3, issue.10, pp.1221-1225, 2004.
DOI : 10.4161/cc.3.10.1164

A. Sartore-bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti et al., PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies, Cancer Research, vol.69, issue.5, pp.1851-1858, 2009.
DOI : 10.1158/0008-5472.CAN-08-2466

H. Prenen, D. Schutter, J. Jacobs, B. , D. Roock et al., PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer, Clinical Cancer Research, vol.15, issue.9, pp.3184-3192, 2009.
DOI : 10.1158/1078-0432.CCR-08-2961

J. Tol, J. Dijkstra, M. Klomp, S. Teerenstra, M. Dommerholt et al., Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab, European Journal of Cancer, vol.46, issue.11, pp.1997-2009, 1997.
DOI : 10.1016/j.ejca.2010.03.036

K. Zhu, H. Yan, R. Wang, H. Zhu, X. Meng et al., Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer, Medical Oncology, vol.18, issue.8, pp.14-0016, 2014.
DOI : 10.1007/s12032-014-0016-6

H. Blons, E. Rouleau, N. Charrier, G. Chatellier, J. Cote et al., Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience, PLoS ONE, vol.12, issue.7, p.68945, 2013.
DOI : 10.1371/journal.pone.0068945.s002

URL : https://hal.archives-ouvertes.fr/hal-00974911

A. Harle, C. Dubois, M. Rouyer, and J. Merlin, [Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay], Ann Biol Clin, vol.71, issue.5, pp.603-610, 2013.

D. Tougeron, T. Lecomte, J. Pages, C. Villalva, C. Collin et al., Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Annals of Oncology, vol.24, issue.5, pp.1267-73, 2013.
DOI : 10.1093/annonc/mds620

A. Harle, M. Lion, N. Lozano, and J. Merlin, [Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer], Bull Cancer, vol.100, issue.10, pp.947-54, 2013.

A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011.
DOI : 10.3322/caac.20107

W. De-roock, H. Piessevaux, D. Schutter, J. Janssens, M. et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-523, 2008.
DOI : 10.1093/annonc/mdm496

S. Khambata-ford, C. Garrett, N. Meropol, M. Basik, C. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

A. Custodio and J. Feliu, Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations, Critical Reviews in Oncology/Hematology, vol.85, issue.1, pp.45-81, 2013.
DOI : 10.1016/j.critrevonc.2012.05.001

P. Laurent-puig, A. Cayre, G. Manceau, E. Buc, J. Bachet et al., Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5954, 2009.
DOI : 10.1200/JCO.2008.21.6796

URL : https://hal.archives-ouvertes.fr/hal-00618089

G. Perkins, A. Lievre, C. Ramacci, T. Meatchi, A. De-reynies et al., Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6, pp.1321-1352, 2010.
DOI : 10.1002/ijc.25152

F. Chergui, A. Chretien, S. Bouali, C. Ramacci, M. Rouyer et al., Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1363, 2009.
DOI : 10.1373/clinchem.2008.116632

F. Harrell, J. Lee, K. Mark, and D. , MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-87, 1996.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

W. Sauerbrei and M. Schumacher, A bootstrap resampling procedure for model building: Application to the cox regression model, Statistics in Medicine, vol.42, issue.16, pp.2093-109, 1992.
DOI : 10.1002/sim.4780111607

S. Iwamoto, S. Hazama, T. Kato, Y. Miyake, M. Fukunaga et al., Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study, Anticancer Res, vol.34, issue.4, pp.1967-73, 2014.

E. Razis, G. Pentheroudakis, G. Rigakos, M. Bobos, G. Kouvatseas et al., EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab, Journal of Cancer Research and Clinical Oncology, vol.351, issue.4, pp.737-785, 2014.
DOI : 10.1158/0008-5472

O. Mirzoeva, D. Das, L. Heiser, S. Bhattacharya, D. Siwak et al., Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition, Cancer Research, vol.69, issue.2, pp.565-72, 2009.
DOI : 10.1158/0008-5472.CAN-08-3389

O. Saglam, C. Garrett, D. Boulware, Z. Sayegh, D. Shibata et al., Activation of the Serine/Threonine Protein Kinase AKT During the Progression of Colorectal Neoplasia, Clinical Colorectal Cancer, vol.6, issue.9, pp.652-658, 2007.
DOI : 10.3816/CCC.2007.n.034

W. De-roock, D. Vriendt, V. Normanno, N. Ciardiello, F. et al., KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, The Lancet Oncology, vol.12, issue.6, pp.594-603, 2011.
DOI : 10.1016/S1470-2045(10)70209-6

W. Jeong, P. Cha, and K. Choi, Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer, World Journal of Gastroenterology, vol.20, issue.29, pp.9862-71, 2014.
DOI : 10.3748/wjg.v20.i29.9862

E. Agarwal, A. Chaudhuri, P. Leiphrakpam, K. Haferbier, M. Brattain et al., Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer, BMC Cancer, vol.20, issue.11, pp.1471-2407, 2014.
DOI : 10.1093/emboj/20.11.2723

H. Kantarjian, N. Shah, A. Hochhaus, J. Cortes, S. Shah et al., Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2260-70, 2010.
DOI : 10.1056/NEJMoa1002315

G. Saglio, D. Kim, S. Issaragrisil, P. Le-coutre, G. Etienne et al., Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2251-2260, 2010.
DOI : 10.1056/NEJMoa0912614

X. Yang, K. Yang, and K. Kuang, The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review, Current Oncology Reports, vol.50, issue.4, pp.14-0390, 2014.
DOI : 10.1007/s11912-014-0390-4

K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford et al., Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations, New England Journal of Medicine, vol.367, issue.18, pp.1694-703, 2012.
DOI : 10.1056/NEJMoa1210093

S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau et al., Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.367, issue.19, pp.1783-91, 2012.
DOI : 10.1056/NEJMoa1209124

Y. Narita, H. Taniguchi, A. Komori, S. Nitta, K. Yamaguchi et al., CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy, Cancer Chemotherapy and Pharmacology, vol.104, issue.9783, pp.409-425, 2014.
DOI : 10.1007/s00280-013-2367-7

P. Hegde, A. Jubb, D. Chen, N. Li, Y. Meng et al., Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab, Clinical Cancer Research, vol.19, issue.4, pp.929-966, 2013.
DOI : 10.1158/1078-0432.CCR-12-2535

J. Cai, H. Ma, F. Huang, D. Zhu, J. Bi et al., Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis, World Journal of Surgical Oncology, vol.11, issue.1, pp.1477-7819, 2013.
DOI : 10.1200/JCO.2008.16.1612

V. Stiegelbauer, S. Perakis, A. Deutsch, H. Ling, A. Gerger et al., MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer, World Journal of Gastroenterology, vol.20, issue.33, pp.11727-11762, 2014.
DOI : 10.3748/wjg.v20.i33.11727

T. Hansen, B. Nielsen, F. Sorensen, A. Johnsson, and A. Jakobsen, Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer, Molecular Cancer Therapeutics, vol.13, issue.9, pp.2238-2283, 2014.
DOI : 10.1158/1535-7163.MCT-14-0131

K. Polyak, Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution, Nature Medicine, vol.57, issue.4, pp.344-350, 2014.
DOI : 10.1038/nature10762

K. Taqman and P. , and high resolution melting PCR assays for the detection of KRAS somatic Bibliographie 186 mutations in formalin-fixed paraffin embedded colorectal carcinomas, Virchows Arch, vol.462, issue.3, pp.329-364, 2013.

C. Yun, K. Mengwasser, A. Toms, M. Woo, H. Greulich et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proceedings of the National Academy of Sciences, vol.105, issue.6, pp.2070-2075, 2008.
DOI : 10.1073/pnas.0709662105

V. Hofman, M. Ilie, V. Gavric-tanga, V. Lespinet, M. Mari et al., R??le du laboratoire d???anatomie pathologique dans l???approche pr??-analytique des examens de biologie mol??culaire r??alis??s en pathologie tumorale, Annales de Pathologie, vol.30, issue.2, pp.85-93, 2010.
DOI : 10.1016/j.annpat.2010.03.003

N. West, M. Dattani, P. Mcshane, G. Hutchins, J. Grabsch et al., The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients, British Journal of Cancer, vol.26, issue.10, pp.1519-1542, 2010.
DOI : 10.1016/j.humpath.2007.04.008

G. Improta, A. Zupa, L. Possidente, A. Tartarone, P. Pedicini et al., Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity, Oncology Letters, vol.5, issue.5, pp.1741-1744, 2013.
DOI : 10.3892/ol.2013.1255

B. Vider, A. Zimber, E. Chastre, S. Prevot, C. Gespach et al., Evidence for the involvement of the Wnt 2 gene in human colorectal cancer, Oncogene, vol.12, issue.1, pp.153-161, 1996.

T. Boudawara and M. Frikha, Downregulation of WIF-1 and Wnt5a in patients with colorectal carcinoma: clinical significance, Tumour Biol, vol.35, issue.8, pp.7975-82, 2014.

A. Sebio, M. Kahn, and H. Lenz, The potential of targeting Wnt/??-catenin in colon cancer, Expert Opinion on Therapeutic Targets, vol.162, issue.6, pp.611-616, 2014.
DOI : 10.1517/14728222.2014.906580

M. Slattery, A. Lundgreen, S. Kadlubar, K. Bondurant, R. Wolff et al., JAK/STAT/SOCS-signaling pathway and colon and rectal cancer, Molecular Carcinogenesis, vol.30, issue.2, pp.155-66, 2013.
DOI : 10.1002/mc.21841

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430812

C. Gordziel, J. Bratsch, R. Moriggl, T. Knosel, and K. Friedrich, Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma, British Journal of Cancer, vol.40, issue.1, pp.138-184, 2013.
DOI : 10.1515/bc.2011.038

G. Nagaraju, W. Park, J. Wen, H. Mahaseth, J. Landry et al., Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3, Angiogenesis, vol.16, issue.4, pp.903-920, 2013.

L. Zhang, J. Li, L. Li, J. Zhang, X. Wang et al., IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway, Carcinogenesis, vol.35, issue.6, pp.1330-1370, 2014.
DOI : 10.1093/carcin/bgu017

S. Wang, J. Hu, Q. Guo, Y. Zhao, J. Cheng et al., AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway, Oncology Reports, issue.10, p.20143477, 2014.
DOI : 10.3892/or.2014.3477

A. Cuenda and S. Rousseau, p38 MAP-Kinases pathway regulation, function and role in human diseases, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1358-75, 2007.
DOI : 10.1016/j.bbamcr.2007.03.010

M. De-la-cruz-morcillo, M. Valero, J. Callejas-valera, L. Arias-gonzalez, P. Melgar-rojas et al., P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance, Oncogene, vol.126, issue.9, pp.1073-85, 2012.
DOI : 10.1007/s004320050286

F. Chiacchiera, V. Grossi, M. Cappellari, A. Peserico, M. Simonatto et al., Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models, Cancer Letters, vol.324, issue.1, pp.98-108, 2012.
DOI : 10.1016/j.canlet.2012.05.006

T. Lecomte, A. Berger, F. Zinzindohoue, S. Micard, B. Landi et al., Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, International Journal of Cancer, vol.11, issue.5, pp.542-550, 2002.
DOI : 10.1002/ijc.10526

S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.102, issue.7404, pp.532-538, 2012.
DOI : 10.1038/nature11156

A. Thierry, F. Mouliere, E. Messaoudi, S. Mollevi, C. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, vol.2, issue.4, pp.430-435, 2014.
DOI : 10.1038/nm.3511

A. Kalikaki, H. Politaki, J. Souglakos, S. Apostolaki, E. Papadimitraki et al., KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer, PLoS ONE, vol.18, issue.8, p.2014, 2014.
DOI : 10.1371/journal.pone.0104902.t004

U. Bork, R. Grutzmann, N. Rahbari, S. Scholch, M. Distler et al., Prognostic relevance of minimal residual disease in colorectal cancer, World Journal of Gastroenterology, vol.20, issue.30, pp.10296-304, 2014.
DOI : 10.3748/wjg.v20.i30.10296

P. Chen, Q. Xi, Q. Wang, and P. Wei, Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer, Medical Oncology, vol.31, issue.6, p.31235, 2014.
DOI : 10.1007/s12032-014-0235-x

G. Manceau, S. Imbeaud, R. Thiebaut, F. Liebaert, K. Fontaine et al., Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy, Clinical Cancer Research, vol.20, issue.12, pp.3338-3385, 2014.
DOI : 10.1158/1078-0432.CCR-13-2750

I. Wiechers, N. Perin, and R. Cook-deegan, The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, Genome Med, vol.5, issue.9, p.2013, 1990.

J. Hamfjord, A. Stangeland, T. Hughes, M. Skrede, K. Tveit et al., Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing, PLoS ONE, vol.70, issue.4, p.17, 2012.
DOI : 10.1371/journal.pone.0034150.s007

H. Wang, L. Yan, Q. Shao, S. Fu, Z. Zhang et al., Profiling Plasma MicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing, Clinical Chemistry, vol.60, issue.5, pp.773-82, 2014.
DOI : 10.1373/clinchem.2013.214213

Y. Yoshimura, M. Tomita, F. Mizutani, and T. Yasukawa, Cell Pairing Using Microwell Array Electrodes Based on Dielectrophoresis, Analytical Chemistry, vol.86, issue.14, pp.6818-6840, 2014.
DOI : 10.1021/ac5015996

. Dans, abord développé des techniques pour le génotypage des gènes RAS et PIK3CA à partir d'échantillons de tumeurs colorectales fixées au formol et incluses en paraffine, puis dans un second temps, nous avons validé ces méthodes selon la norme ISO 15189, puis dans un dernier temps, nous avons étudié l'expression des phosphoprotéines en aval des récepteurs à l'EGF ainsi que les statuts mutationnels des gènes KRAS

. Notre-Étude-montre and . Qu, associer la mesure de l'expression des phosphoprotéines de signalisation en aval d'EGFR, à l'analyse du statut mutationnel des gènes RAS, BRAF, PIK3CA pourrait présenter un intérêt dans la prédiction de la réponse aux thérapies anti-EGFR chez les patients atteints d'un cancer colorectal métastatique